Expression of HER2 and bradykinin B1 receptors in precursor lesions of gallbladder carcinoma

Table 1 Clinical and pathological data of patients with gallbladder adenomas, adenocarcinoma and its putative precursor lesions

Lesion	Sex	Age (yr, mean ± SD)
Normal mucosa (n = 5)	F (5)	54.6 ± 9.0
Pyloric adenoma (n = 15)	F (13)/M (2)	55.2 ± 3.5
Intestinal adenoma (n = 6)	F (6)	68.5 ± 1.7
Pyloric-type metaplasia (n = 20)	F (20)	51.5 ± 3.2
Intestinal metaplasia (n = 24)	F (24)	50.0 ± 3.4
Carcinoma in situ (n = 10)	F (9)/M (1)	65.8 ± 2.5
Invasive carcinoma (n = 12)	F (9)/M (3)	66.0 ± 3.8

According to WHO classification. F: Female; M: Male.

Table 2 Primary antibody sources, dilutions, antigen retrieval and incubation conditions

Antibody	Source	Dilution/incubation	Microwave antigen retrieval
HER2	Novocastra, NCL-CBE-356	1:200/overnight	No
Bradykinin B1R	Santa Cruz, sc-25484	1:300/overnight	90 °C/7 min, Tris-HCl buffer pH 10
	Merck	1:500/overnight	No
Ki-67	Dako, A0047	1:200/overnight	90 °C/15 min, Citrate buffer pH 6

Table 3 Expression of immunoreactive HER2, bradykinin B₁ receptor and Ki-67 in gallbladder adenomas and in adenocarcinoma and its putative precursor lesions (%)

Receptor/marker	Normal epithelium	Pyloric adenoma	Intestinal adenoma	Intestinal metaplasia	Carcinoma in situ	Invasive carcinoma
HER2	0/5	0/14	1/6 (17)	22/24 (91.7)a	9/10 (90)a	4/12 (33)
Bradykinin B1R	0/5	10/15 (67)a	6/6 (100)a	24/24 (100)a	10/10 (100)a	1/12 (8.3)
Ki-671	0.05 ± 0.005 (1.1)	0.05 ± 0.01 (5.1)	0.10 ± 0.01 (10.8)	0.36 ± 0.03b (36.7)	0.37 ± 0.05b (37.5)	0.42 ± 0.03b (42)

¹Proliferation index estimated as immunoreactivity to Ki-67 antigen.

^aP < 0.05,

^bP < 0.01 vs normal epithelium. B₁R: B₁ receptor.